Yahoo
NasdaqCM - Nasdaq Real Time Price USD

BriaCell Therapeutics Corp. (BCTX)

3.6991 +0.0041 (+0.11%)
As of 3:18:45 PM EST. Market Open.

Key Executives

Amounts are as of December 31, 2026 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Dr. William V. Williams FCPA, M.D.
CEO, President & Director 872.35k -- 1955
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A.
CFO & Corporate Secretary 564.59k -- 1973
Dr. Giuseppe Del Priore M.D., M.P.H.
Chief Medical Officer 625.4k -- 1962

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 -15th Street
West Vancouver, BC V7T 2X1
Canada
604-921-1810 https://briacell.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
31

Description

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.

Corporate Governance

BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

October 28, 2026 at 12:00 AM UTC

10-K: Periodic Financial Reports

June 26, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

June 9, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 3, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 31, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

March 10, 2026 at 12:00 AM UTC

10-Q: Periodic Financial Reports

March 9, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 20, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 12, 2026 at 12:00 AM UTC

DEF 14A: Proxy Statements

January 15, 2026 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: